2,6-Diamino-3,5-dicyan-pyrazin. | 39870-52-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,6-Diamino-3,5-dicyan-pyrazin.
• 英文别名: 3,5-Diamino-2,6-dicyan-pyrazin；3,5-diamino-2,6-dicyanopyrazine；3,5-dicyano-2,6-diaminopyrazine；3,5-diamino-pyrazine-2,6-dicarbonitrile；3,5-diaminopyrazine-2,6-dicarbonitrile
• CAS: 39870-52-5
• 化学式: C₆H₄N₆
• 分子量: 160.138
• InChiKey: YYRZHBNPCYGDJD-UHFFFAOYSA-N

物化性质

• 沸点：
  521.1±50.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,6-Diamino-3,5-dicyan-pyrazin. 、 sodium hydroxide 、 氨 、 水 在 3,5-Diamino-2,6-dicarbamoyl-pyrazin 、 氮 、 ice 作用下， 反应 3.9h， 以resulted in the precipitation of 3.30 g (16.9 mmol) of 3,5-diamino-2,6-dicarbamoylpyrazine which的产率得到3,5-Diamino-2,6-dicarbamoyl-pyrazin
  参考文献：
  名称：

  Synthesis of 3,5-diaminopyrazinoic acid from

  摘要：

  本文描述了一种改进的制备3,5-二氨基吡嗪酸（用于制造利尿剂）的方法。该过程中获得的新化合物包括3,5-二氨基-2,6-二甲酰基吡嗪；3.5-二氨基-6-甲酰基吡嗪酸和3,5-二氨基-6-甲酰基吡嗪。后两种化合物也可用作环氧树脂的固化剂。

  公开号：

  US03948895A1

文献信息

• [EN] COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE<br/>[FR] COMPOSITIONS ET MÉTHODES POUR ÉVALUER LE SYSTÈME VASCULAIRE DE L'ŒIL
  申请人：MEDIBEACON INC

  公开号：WO2016183351A1

  公开（公告）日：2016-11-17

  The present disclosure relates to compositions and methods for assessing blood vessels and organs of the body, more specifically to methods for assessing the vasculature of the eye.

  本公开涉及用于评估人体血管和器官的组合物和方法，更具体地说是用于评估眼部血管的方法。
• DICYANOPYRAZINE COMPOUND, LUMINESCENT MATERIAL, LUMINESCENCE DEVICE USING THE SAME, AND METHOD FOR PRODUCING 2,5-DICYANO-3,6-DIHALOGENOPYRAZINE
  申请人：KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

  公开号：US20180273513A1

  公开（公告）日：2018-09-27

  A compound represented by formula (I) or formula (1I): in formula (I), R 3 represents an electron donating group, R 4 represents a hydrogen atom, a substituted or unsubstituted aryl group or an electron donating group, L 3 represents a substituted or unsubstituted heteroarylene group or a substituted or unsubstituted arylene group, L 4 represents a single bond, a substituted or unsubstituted heteroarylene group or a substituted or unsubstituted arylene group, L 3 and L 4 may bond together to form a ring with the carbon atoms to which they are bonded, in formula (II), R 5 represents an electron donating group, R 6 represents a hydrogen atom, a substituted or unsubstituted aryl group or an electron donating group, L 5 represents a substituted or unsubstituted heteroarylene group or a substituted or unsubstituted arylene group, L 6 represents a single bond, a substituted or unsubstituted heteroarylene group or a substituted or unsubstituted arylene group.

  化合物的化学式为(I)或(II)：在化学式(I)中，R3代表一个电子给体基团，R4代表一个氢原子，一个取代或未取代的芳基团或一个电子给体基团，L3代表一个取代或未取代的杂芳基团或一个取代或未取代的芳基团，L4代表一个单键，一个取代或未取代的杂芳基团或一个取代或未取代的芳基团，L3和L4可以结合形成一个与它们所连接的碳原子形成环， 在化学式(II)中，R5代表一个电子给体基团，R6代表一个氢原子，一个取代或未取代的芳基团或一个电子给体基团，L5代表一个取代或未取代的杂芳基团或一个取代或未取代的芳基团，L6代表一个单键，一个取代或未取代的杂芳基团或一个取代或未取代的芳基团。
• [EN] PYRAZINE DERIVATIVES FOR OPTICAL IMAGING AND THERAPY<br/>[FR] DÉRIVÉS DE PYRAZINE POUR IMAGERIE OPTIQUE ET THÉRAPIE
  申请人：MALLINCKRODT INC

  公开号：WO2010121003A1

  公开（公告）日：2010-10-21

  The invention provides compounds, including compositions, preparations and formulations, and methods of using and making such compounds. Compounds of the present invention include pyrazine derivatives having a pyrazine core and a plurality of substituents. In some embodiments, pyrazine derivatives of the invention are pyrazine core compounds having one or more electron donating groups and one or more electron withdrawing groups optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.

  本发明提供了化合物，包括组合物、制剂和配方，以及使用和制备这些化合物的方法。本发明的化合物包括具有吡嗪核和多个取代基的吡嗪衍生物。在一些实施例中，本发明的吡嗪衍生物是具有一个或多个电子给体基团和一个或多个电子受体基团的吡嗪核化合物，可选择性地官能化以提供有用的光学、生物、药代动力学和/或物理性质。
• [EN] MODIFIED PYRAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS MODIFIÉS DE PYRAZINE ET LEURS UTILISATIONS
  申请人：MALLINCKRODT INC

  公开号：WO2010078025A1

  公开（公告）日：2010-07-08

  Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.

  本文提供了含有多个聚乙二醇取代基的吡嗪衍生物的化合物、制剂和配方。其中许多化合物可通过受试者或患者的肾系统排泄，并可用于可视化受试者或患者的肾系统。在电磁辐射的激发下，本文披露的一些化合物表现出发光性，并在患者或受试者的体液中存在时可外部检测到。本文还提供了可视化受试者或患者的肾系统的方法。
• Pyrazine Derivatives and Uses Thereof in Renal Monitoring
  申请人：Rajagopalan Raghavan

  公开号：US20120100078A1

  公开（公告）日：2012-04-26

  The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X 1 to X 4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y 1 to Y 4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

  本发明涉及吡嗪衍生物，如下式I和II所示。化合物的X1到X4可以被表征为电子吸引基团。相反，化合物的Y1到Y4可以被表征为电子供给基团。本发明的吡嗪衍生物可用于评估肾功能。特别地，可以将本发明的吡嗪衍生物的有效量注入患者体内。体内的吡嗪衍生物可以暴露于可见光和/或红外光以使其发出光谱能量。可以检测和利用这种发出的光谱能量来确定患者的肾功能。